Cell Therapy News

Sixty-five percent of patients with relapsed or refractory follicular lymphoma had an initial complete response to a single infusion of tisagenlecleucel, according to phase 2 study results presented at TCT Meetings Digital Experience.

Long-term follow-up data showed betibeglogene autotemcel to be a safe and efficacious treatment for patients with transfusion-dependent beta-thalassemia, according to study results presented at TCT Meetings Digital Experience.

Gene therapy developer bluebird bio suspended clinical trials using its LentiGlobin product for sickle cell disease due to reported cases of hematologic malignancies among patients who received the treatment.

An investigational chimeric antigen receptor T-cell therapy appeared safe and demonstrated antitumor activity among patients with relapsed or refractory B-cell malignancies, according to results presented at TCT Meetings Digital Experience.

Combining natural killer cells with high-dose chemotherapy and autologous stem cell transplant did not increase toxicity among patients with B-cell non-Hodgkin lymphoma, according to results presented at TCT Meetings Digital Experience.

Children and young adults with acute lymphoblastic leukemia who received higher doses of tisagenlecleucel achieved significantly longer OS and RFS, according to study results presented at TCT Meetings Digital Experience.

Younger Black patients who received tisagenlecleucel for acute lymphoblastic leukemia had significantly poorer outcomes than those of other races or ethnicities, according to results presented at TCT Meetings Digital Experience.

The Institute for Clinical and Economic Review published a draft evidence report assessing the comparative clinical effectiveness and value of B-cell maturation antigen-directed therapies for heavily pretreated multiple myeloma.

The FDA cleared an investigational new drug application for KITE-222, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory acute myeloid leukemia, according to the agent’s manufacturer.

Center for International Blood and Marrow Transplant will present awards to two clinicians during this year’s TCT Meetings Digital Experience.